Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2025

Segment Reporting [Abstract]

Schedule of reportable segment net income (loss)

The Company's reportable segment net income (loss) for the three months ended March 31, 2025 and 2024, consisted of the following (in thousands):

	Three Months Ended March 31,
	2025			2024
Significant segment expenses:
Live biotherapeutics platform	$	5,123		$	9,164
SER-155		577			2,400
R&D personnel-related (including stock-based compensation)		6,118			7,845
G&A personnel-related (including stock-based compensation)		4,173			6,641
Professional fees		3,180			2,628
Facility-related and other		4,535			5,675
Gain on sale of VOWST Business		(52,181	)		-
Other segment expense (income) (1)		(4,207	)		(1,450	)
Net income (loss) from continuing operations		32,682			(32,903	)
Net (loss) from discontinued operations, net of tax (2)		-			(7,230	)
Net income (loss)	$	32,682		$	(40,133	)